Kala Bio KALA

KALA BIO, Inc. is a biopharmaceutical company in transition. The company was originally incorporated under the laws of the State of Delaware in July 2009 and changed its name from Kala Pharmaceuticals Inc to KALA BIO, Inc on August 2 2023. Historically it focused on the research development and commercialization of innovative therapies for rare and severe diseases of the front and back of the eye. Its lead product candidate was KPI 012 a mesenchymal stem cell secretome derived from human bone marrow that was being evaluated for the treatment of persistent corneal epithelial defects. After the CHASE trial did not meet its primary endpoint the company halted development of KPI 012 and the mesenchymal stem cell secretome platform. KALA BIO, Inc. now evaluates strategic alternatives for its legacy biologics assets while concurrently developing an artificial intelligence infrastructure platform called Researgency for deployment within biotechnology and pharmaceutical customer environments. The firm retains worldwide commercial rights for its mesenchymal stem cell secretome platform including KPI 012 and KPI 014 and owns or exclusively licenses a portfolio of patents that are expected to expire no earlier than 2040. As of the date of this filing the company employs a small team of full time professionals and maintains its headquarters in Waltham Massachusetts.

The company does not currently generate revenue from product sales as it has no approved therapies on the market. Potential near term revenue could arise from licensing or sale of its mesenchymal stem cell secretome intellectual property including the KPI 012 and KPI 014 asset portfolios and associated patents. The firm is also eligible to receive milestone payments from prior asset sales such as the agreement with Alcon for EYSUVIS and INVELTYS although no milestones have been achieved to date. In addition KALA BIO, Inc. anticipates future revenue from offering Researgency as a platform as a service to biotechnology and pharmaceutical companies that wish to run artificial intelligence workloads on premises while retaining control of their proprietary data. The company may also explore collaborative arrangements co development agreements and other strategic partnerships that could generate upfront payments royalties or revenue sharing based on the success of its biologics or AI initiatives.

The company operates through the following segments.

• The Biologics segment encompasses the company's mesenchymal stem cell secretome platform including the product candidates KPI 012 and KPI 014 associated patents know how regulatory materials and manufacturing expertise.

• This segment focuses on preserving and seeking to monetize these assets through licensing sale out licensing collaboration or other arrangements with third parties while also evaluating potential preclinical activities if additional funding and suitable partners become available.

• The segment further includes efforts to protect the intellectual property portfolio through patent maintenance trade secret safeguards and continued engagement with the United States Patent and Trademark Office and foreign patent authorities.

• The AI segment consists of the Researgency platform obtained via an exclusive license from Younet AI.

• This segment aims to develop and deploy a dedicated on premises artificial intelligence infrastructure solution for biotechnology and pharmaceutical companies offering capabilities such as multi agent workflow orchestration biological data analysis regulatory pathway optimization safety and efficacy modeling and intellectual property management while ensuring data remains within the customer's environment.

• The segment also involves internal validation using the KPI 012 clinical dataset to generate reference case studies refine platform functionality and assess commercial feasibility before pursuing external customer engagements.

KALA BIO, Inc. occupies a niche position at the intersection of biologics intellectual property and artificial intelligence infrastructure for the life sciences sector. In the biologics arena the company competes with larger pharmaceutical and biotechnology firms that have greater financial resources and established commercial platforms but differentiates itself through its proprietary mesenchymal stem cell secretome data and patent portfolio extending to 2040. In the artificial intelligence platform market for biotechnology the company faces competition from large technology companies offering general purpose AI cloud services and from specialized drug discovery AI firms that possess larger research teams and broader commercial relationships. KALA BIO, Inc. believes its competitive advantages lie in its on premises deployment model its deep domain expertise in ophthalmic biologics development and its exclusive access to the KPI 012 clinical dataset which can be used to validate and refine the Researgency platform. The firm also leverages its experience with regulatory submissions clinical trial conduct and data governance to address customer concerns about data sovereignty auditability and compliance with health information privacy laws such as HIPAA and GDPR.

The company's customers for the biologics segment are expected to include pharmaceutical corporations biotechnology firms and potential licensing partners interested in acquiring or collaborating on mesenchymal stem cell secretome assets. For the AI segment the intended customer base comprises biotechnology and pharmaceutical companies contract research organizations and academic research institutions that seek to run artificial intelligence workloads on premises while maintaining full control over their proprietary biological data and regulatory documents. KALA BIO, Inc. also anticipates interest from government research agencies and nonprofit organizations that require secure AI environments for processing sensitive health information. The firm intends to tailor its sales and marketing efforts to these groups through direct outreach strategic partnerships and participation in industry conferences and workshops.